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A B S T R A C T
Cerebrospinal fluid (CSF) concentration–time
curves of rifampicin and fusidic acid were studied
in a patient with post-operative meningitis caused
by Staphylococcus epidermidis. The patient was
treated with this combination of antimicrobial
agents because of a severe hypersensitivity reac-
tion to vancomycin. Peak CSF concentrations of
rifampicin exceeded the MIC by > 60-fold, while
those of fusidic acid just reached the MIC. CSF
concentrations of fusidic acidwere relatively stable
within the range reported for patients with unin-
flamed meninges, but serum levels were surpris-
ingly low. An increase in the metabolism of fusidic
acid induced by rifampicin cannot be excluded.
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Data on the pharmacokinetics of rifampicin and
fusidic acid in cerebrospinal fluid (CSF) are
limited. Therefore, it was of interest to study the
drug concentration–time curves in a patient with
post-operative ventricular drain-associated Sta-
phylococcus epidermidis meningitis. The patient
was treated with this combination because of a
severe hypersensitivity reaction to vancomycin,
which is used commonly for the treatment of
post-surgical nosocomial meningitis [1,2].
The patient was a 55-year-old man with a
massive sub-arachnoid haemorrhage and acute
hydrocephalus. The aneurysm was embolised and
CSF drainage was started. Three weeks later, the
patient developed meningitis. The CSF showed
marked pleocytosis and yielded an isolate of
S. epidermidis that was resistant to all antibiotics
tested except vancomycin, rifampicin and fusidic
acid. Despite ventricular catheter removal and
treatment with intravenous vancomycin for
1 week, the patient’s condition deteriorated. A
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new ventricular catheter was inserted and vanco-
mycin 10 mg once-daily was administered. How-
ever, an allergic reaction with severe respiratory
obstructivity and exanthema developed after
6 days. The treatment was changed to fusidic acid
and rifampicin, which were given intravenously
in doses of 500 mg three-times-daily and 900 mg
once-daily, respectively (see below). The patient
improved after treatment for several days, and the
ventricular catheter was removed after 12 days,
but meningitis reoccurred after a further 2 days.
CSF culture yielded a S. epidermidis isolate that
was now resistant to both rifampicin and fusidic
acid. Differences in morphology, biochemistry
and API Staph (bioMe´rieux, Marcy l’E´toile,
France) profile, and a different pulsed-field gel
electrophoresis pattern [3], suggested that this was
not the same strain as the first isolate. This second
episode of meningitis was treated successfully
with intravenous and intraventricular vancomy-
cin given with steroid protection.
The initial meningitic episode was treated with
rifampicin (Rimactan; Swedish Orphan AB, Stock-
holm, Sweden) and fusidic acid (Fusidin; Leo
Pharma AB, Malmo¨, Sweden), given in different
lines as infusions over a 3-h period. After removal
of the catheter, CSF samples of 1–2 mL were
drawn repeatedly, concomitantly with blood
samples, on treatment days 2 and 4. On day 9,
two pairs of blood and CSF samples were drawn
before and 6 h after the start of the antibiotic
infusions. Serum and CSF samples were stored at
) 20 C pending analysis.
MICs for the original isolate were determined
by a broth macrodilution method [4], and were
found to be 0.016 mg ⁄L and 0.25 mg ⁄L for rif-
ampicin and fusidic acid, respectively. Serum and
CSF concentrations of rifampicin were deter-
mined with a precision of 15% by an agar
well diffusion assay with a test organism,
Staphylococcus aureus stain Sa275, resistant to
fusidic acid [5]. As microbiological methods were
not sufficiently sensitive to measure fusidic acid
concentrations in CSF and serum, these were
determined by reverse phase high-performance
liquid chromatography with a precision of 8% [6].
CSF and serum concentrations of rifampicin are
shown in Fig. 1. The CSF samples that were
obtained 1 week later had considerably lower
concentrations at t0 and t6 h (0.1 mg ⁄L and
0.5 mg ⁄L, respectively) than those obtained on
days 2 and 4. The serum concentrations were also
correspondingly lower (< 0.5 mg ⁄L and
6.9 mg ⁄L, respectively). The CSF and serum
concentrations of fusidic acid are shown in
Fig. 2. One week later, the serum concentrations
at t0 and t6 h were reduced to 1.7 mg ⁄L and
8.1 mg ⁄L, respectively, while the CSF fusidic
acid concentration was unchanged. The serum
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Fig. 1. Cerebrospinal fluid (CSF) concentration–time curve
of rifampicin on day 2 and day 4 after initiation of
intravenous treatment with rifampicin 900 mg once-daily
(body weight 85 kg). The CSF volumes produced were
150 mL ⁄ 24 h and 105 mL ⁄ 24 h, respectively. The serum (S)
curve represents the mean of the values obtained on day 2
and day 4. There were no significant differences in the
serum concentrations between day 2 and day 4.
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Fig. 2. Cerebrospinal fluid (CSF) concentration–time curve
of fusidic acid on day 2 and day 4 after initiation of
intravenous treatment with fusidic acid 500 mg three-
times-daily (body weight 85 kg). The CSF volumes pro-
duced were 150 mL ⁄ 24 h and 105 mL ⁄ 24 h, respectively.
The serum (S) curve represents the mean of the values
obtained on day 2 and day 4. On day 4, the serum
concentrations were slightly higher than those on day 2,
with a mean difference of 1.2 mg ⁄L.
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albumin concentrations on days 2, 4 and 9 were
similar (30–31 mg ⁄L).
In agreement with data reported previously, the
rifampicin concentrations in the CSF of the patient
were well above the MIC for the S. epidermidis
isolate, and also above the MICs for other
meningitis-causing bacteria for which treatment
with rifampicin might be an option (e.g., penicil-
lin-resistant pneumococci, Listeria monocytogenes,
Staphylococcus aureus and coagulase-negative
staphylococci [7]). The peak serum concentration
after treatment for 1 week was almost half that
found on the second day of treatment. This was
probably caused by a drug-induced increase in the
metabolism of rifampicin [8].
Since fusidic acid might be an alternative agent
for use in combination with other antibiotics, such
as rifampicin, for the treatment of post-operative
meningitis after neurosurgery or shunt infections
caused by methicillin-resistant coagulase-negat-
ive staphylococci or S. aureus, CSF penetration
data are of interest. To our knowledge, there are
no published data on CSF concentrations of
fusidic acid in patients with meningitis. In the
patient described here, the CSF concentration was
relatively stable, varying only between 0.2 and
0.3 mg ⁄L, which is within the range reported for
patients with uninflamed meninges [9]. Albumin
binding in serum has been reported to be 91–98%
[10], and since the CSF protein concentration in
the patient was < 1% of the serum concentration,
it can be calculated that almost all of the fusidic
acid in the CSF was in the unbound free form. The
concentration found was above or near the MIC
for most coagulase-negative staphylococci and
S. aureus strains [11]. Increased penetration of
fusidic acid has been demonstrated in animals
with purulent CSF [12]. However, in the patient
described here, meningeal inflammation was mild
and serum concentrations were surprisingly low.
In several previous studies, accumulation of
fusidic acid during the first 4 days has been
demonstrated [10,13]. In the present study, the
peak values on days 2 and 4 were 21.6 mg ⁄L and
25.7 mg ⁄L, respectively, which is considerably
lower than reported previously [13]. Fusidic acid
is metabolised in the liver, and inter-subject
variation after intravenous administration has
been calculated as 15–25% [10]. The difference
observed on days 2 and 4 may be within this
range when the decreased serum albumin level
is taken into consideration, but the concentra-
tions observed 1 week later cannot be explained
solely on this basis. A drug interaction, such as
rifampicin-induced increase in the metabolism of
fusidic acid, represents a possible mechanism that
cannot be excluded at present.
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A B S T R A C T
Intravenous drug use (IVDU) remains a major
means of hepatitis C virus (HCV) transmission. In
this study, 101 drug users were studied prospec-
tively after cessation of IVDU. Of these, 75.8%
were anti-HCV positive, and 71.4% had elevated
levels of alanine aminotransferase. These levels
decreased significantly within 1 month of IVDU
cessation (p 0.02). Liver biopsies showed minimal
or mild fibrosis in 32 (71%) of 45 subjects, and
severe fibrosis in two (4.4%) subjects. Anti-HCV-
positive intravenous drug users in this study
presented with mild liver disease and variable
stages of disease progression. Biochemical disease
activity might be affected by IVDU.
Keywords Drug users, hepatitis C, liver function
tests, liver histology
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Following the introduction of blood donor screen-
ing for hepatitis C virus (HCV) infection, intra-
venous drug use (IVDU) remains the major mode
of HCV transmission in developed countries [1].
Anti-HCV prevalence in Germany is c. 1% in
blood donors [2] and 70–80% in intravenous drug
(IVD) users [3]. Currently, there are c. 150 000
HCV-infected IVD users in Germany, and the
number is increasing by c. 10 000 each year [4].
Little is known about the natural course of HCV
infection in IVD users. In patients with post-
transfusion HCV infection, histopathological
alterations appear to be more severe [5]. The
present study aimed to provide prospective data
on anti-HCV prevalence and viraemia in a group
of recently injecting IVD users, and to correlate
these with data regarding alanine aminotransf-
erase (ALT) levels and histopathogical changes.
The study followed a group of 101 consecutive
drug users (91 IVDU; ten non-IVDU) from an in-
patient clinic for drug addicts in Freiburg, Ger-
many, between January 1997 and July 1998. The
mean follow-up period was 8 months (range 2–18
months). After informed written consent was
obtained, each patient was interviewed by means of
a standardised questionnaire to obtain the data listed
in Table 1. All participants had consumed drugs
until 2–3 weeks before entering the clinic. Screen-
ing for continued alcohol or drug consumptionwas
performed through blood and urine tests. Patients
continuing to use drugs or alcohol were excluded
from the study and discharged from the clinic.
All subjects were tested for HCV, hepatitis B
virus (HBV), hepatitis A virus (HAV) and human
immunodeficiency virus (HIV). Sera were tested
for the presence of anti-HCV with a fourth-
generation anti-HCV assay (Monolisa; Sanofi
Diagnostics Pasteur, Marnes-la-Coquette, France)
and a recombinant immunoblot assay (Recomblot;
Table 1. Clinical and serological data of patients in the
study group
Total drug users
n = 101
IVD users
n = 91
Non-IVD users
n = 10
Age, years (mean ± SD) 27.3 ± 5.1
Women 16 (15.8%)
Duration of IVDU NA 5.6 ± 4.4 NA
History of
Jaundice 30 (29.7%) 30 (33.0%) 0
Blood transfusions 2 (2.0%) 2 (2.2%) 0
Tattoos 64 (64.6%) 61 (67.0%) 3 (30.0%)
Hepatomegaly None None None
Anti-HIV1-positive 2 (2.0%)a 2 (2.2%) 0
Anti-HAV-positive 30 (29.7%) 27 (29.7%) 3 (30.0%)
Anti-HBc-positive 43 (42.6%) 42 (46.2%) 1 (10.0%)
HBsAg-positive 4 (4.0%)b 4 (4.4%) 0
Anti-HCV-positive 70 (69.3%)c 69 (75.8%) 1 (10%)
aIncludes one anti-HCV and one anti-HCV ⁄HBsAg-positive subject.
bThree of four had been co-infected with HCV in the absence of HBV DNA.
cIncludes three HBsAg-positive subjects.
IVDU, intravenous drug use; NA, not applicable.
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